Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€67.47

€67.47

0.340%
0.23
0.340%
€79.54
 
18.07.24 / Tradegate WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Gilead Sciences Inc Stock

Gilead Sciences Inc gained 0.340% compared to yesterday.
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
With a target price of 79 € there is a slightly positive potential of 17.09% for Gilead Sciences Inc compared to the current price of 67.47 €.
So far the community has only identified positive things for Gilead Sciences Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Gilead Sciences Inc in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gilead Sciences Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Gilead Sciences Inc 0.340% 4.735% 14.745% -3.172% -7.727% 16.028% 13.015%
Incyte Corp. 0.370% 4.639% 4.895% 9.250% 5.746% -9.584% -15.254%
Regeneron Pharmaceuticals Inc. -1.570% -1.468% 1.323% 51.468% 22.884% 98.260% 267.041%
Exact Sciences -2.760% 5.741% 11.764% -50.034% -36.298% -53.687% -57.878%

Comments

Prediction Buy
Perf. (%) 4.73%
Target price 93.000
Change
Ends at 12.07.25

Gilead Sciences has been on a bit of a rollercoaster lately, but the recent Raymond James upgrade to 'outperform' with a $93 price target has piqued my interest. The stock has lost about 17.6% year-to-date, which sounds concerning, but the analysts see significant upside potential. Plus, Gilead offers a juicy 4.6% dividend yield, which is always a nice bonus. While the pipeline setbacks are worrying, I think the stock is currently undervalued, and the potential rewards outweigh the risks at this point. I'm cautiously optimistic about Gilead's future and think it could be a solid addition to my portfolio.
Show more

Prediction Buy
Perf. (%) 4.39%
Target price 93.000
Change
Ends at 12.07.25

Gilead Sciences seems to be a promising investment opportunity based on the recent news and analyses. The company's stock has been under pressure this year, but the recent upgrade by Raymond James to an 'outperform' rating and a target price of $93 suggests that the stock has significant upside potential. The analysts at Raymond James highlight Gilead's strong fundamentals and believe that the stock is currently undervalued, making it an attractive buy for investors. Additionally, the company's dividend yield of 4.6% provides a nice income stream for those looking for a stable and reliable investment. While past performance is not a guarantee of future results, Gilead's track record and the positive outlook from analysts make it a compelling pick for investors looking to diversify their portfolio with a solid biotech stock.
Show more

Prediction Buy
Perf. (%) 4.39%
Target price 93.000
Change
Ends at 12.07.25

Gilead Sciences has been on a bit of a rollercoaster lately, but I think the stock has solid long-term potential. The recent Raymond James upgrade to 'outperform' with a $93 target price caught my eye. While the stock has lost around 17.6% year-to-date, I believe the current dip presents a buying opportunity for investors willing to look past the short-term pipeline setbacks. Gilead is a leading biotech giant with a diverse portfolio of drugs, including their flagship HIV/AIDS treatments. The analyst commentary highlights the company's strong dividend yield of around 4.6% - not too shabby in this market! Sure, there are always risks in the biotech space, but Gilead's financial stability and R&D capabilities make me optimistic about their ability to weather the storms and deliver solid returns down the line. I'm cautiously bullish on this stock and think it's worth considering for growth-oriented investors with a medium-to-long-term horizon.
Show more